• Battling aging by preserving telomeres could backfire, fueling cancer

    If an anti-aging regimen that involves telomeres – part of the human chromosome – sounds too good to be true, it probably is, says Jens Schmidt, a postdoctoral fellow in the Cech Lab at CU Boulder’s BioFrontiers Institute.

  • Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

    27 percent of heavily pretreated patients saw clinical benefit from the drug, with at least “stable disease” at 24 or more weeks after the start of treatment.

  • CSU veterinarians help bring groundbreaking cancer drug to market

    Through its clinical trials for animal patients, University of Colorado Cancer Center member institution Colorado…

  • Little survival benefit and higher costs in advanced non-small cell lung cancer associated with new drugs

    CU Cancer Center study shows that a decade that saw the development of new therapies for non-small cell lung cancer resulted in little survival benefit for patients with advanced-stage disease.

  • Women’s Event Supports Research

    Cancer assassins. That’s how Julie Clark, creator of Baby Einstein and speaker at this year’s…

Patient Care

Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

27 percent of heavily pretreated patients saw clinical benefit from the drug, with at least “stable disease” at 24 or more weeks after the start of treatment.

Read the rest of this entry

Research

Battling aging by preserving telomeres could backfire, fueling cancer

If an anti-aging regimen that involves telomeres – part of the human chromosome – sounds too good to be true, it probably is, says Jens Schmidt, a postdoctoral fellow in the Cech Lab at CU Boulder’s BioFrontiers Institute.

Read the rest of this entry

Meet the Experts

A conversation with Nobel Laureate, Thomas R. Cech, PhD

In 1982, a young CU chemist named Tom Cech was the first to show that…

Read the rest of this entry